SG Americas Securities LLC Has $128,000 Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID)

SG Americas Securities LLC raised its stake in Ovid Therapeutics Inc. (NASDAQ:OVID) by 52.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,792 shares of the company’s stock after acquiring an additional 13,728 shares during the quarter. SG Americas Securities LLC owned about 0.06% of Ovid Therapeutics worth $128,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in shares of Ovid Therapeutics by 369.5% in the 2nd quarter. BlackRock Inc. now owns 3,408,207 shares of the company’s stock valued at $11,179,000 after purchasing an additional 2,682,320 shares during the last quarter. Madison Avenue Partners LP boosted its stake in Ovid Therapeutics by 95.2% during the 4th quarter. Madison Avenue Partners LP now owns 2,721,051 shares of the company’s stock worth $5,061,000 after acquiring an additional 1,327,029 shares during the last quarter. State Street Corp boosted its stake in Ovid Therapeutics by 435.4% during the 2nd quarter. State Street Corp now owns 1,026,631 shares of the company’s stock worth $3,367,000 after acquiring an additional 834,898 shares during the last quarter. Geode Capital Management LLC boosted its stake in Ovid Therapeutics by 142.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,213,085 shares of the company’s stock worth $3,979,000 after acquiring an additional 713,450 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Ovid Therapeutics by 342.5% during the 2nd quarter. Northern Trust Corp now owns 480,803 shares of the company’s stock worth $1,577,000 after acquiring an additional 372,151 shares during the last quarter. Institutional investors and hedge funds own 72.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on OVID. Wedbush began coverage on shares of Ovid Therapeutics in a research note on Friday, April 5th. They set an “outperform” rating and a $8.00 price objective on the stock. BTIG Research began coverage on shares of Ovid Therapeutics in a research note on Thursday, December 21st. They set a “buy” rating and a $11.00 price objective on the stock.

Insider Activity

In other Ovid Therapeutics news, CEO Jeremy M. Levin acquired 18,248 shares of the stock in a transaction dated Monday, March 18th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $50,364.48. Following the completion of the acquisition, the chief executive officer now directly owns 3,616,715 shares of the company’s stock, valued at $9,982,133.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 12.60% of the stock is owned by corporate insiders.

Ovid Therapeutics Stock Performance

Shares of OVID opened at $3.11 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.55 and a current ratio of 9.55. Ovid Therapeutics Inc. has a twelve month low of $2.57 and a twelve month high of $4.14. The firm’s 50 day moving average price is $3.27 and its two-hundred day moving average price is $3.36. The firm has a market cap of $219.91 million, a P/E ratio of -4.15 and a beta of 0.71.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings results on Friday, March 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). Ovid Therapeutics had a negative net margin of 13,351.53% and a negative return on equity of 49.76%. The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.10 million. On average, analysts forecast that Ovid Therapeutics Inc. will post -0.65 EPS for the current fiscal year.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.